The Metabolic Landscape of RAS-Driven Cancers from biology to therapy
Suman Mukhopadhyay1,2, Matthew G Vander Heiden3,4, Frank McCormick5,6
1National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Abstract:
Our understanding of how the RAS protein family, and in particular mutant KRAS promote metabolic dysregulation in cancer cells has advanced significantly over the last decade. In this Review, we discuss the metabolic reprogramming mediated by oncogenic RAS in cancer, and elucidating the underlying mechanisms could translate to novel therapeutic opportunities to target metabolic vulnerabilities in RAS-driven cancers.
Insights
Oncogenic RAS proteins, especially mutant KRAS, drive cancer cell metabolic dysregulation. Understanding these mechanisms reveals new therapeutic targets for RAS-driven cancers.
Area of Science:
- Oncology
- Molecular Biology
- Metabolic Pathways
Related Concept Videos
The Ras Gene
Ras is a...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Abnormal Proliferation


